Paper15959528
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.
Yanada M and 4 others. Leukemia, 2005. Cited by 227 papers, by iCite.
Cite this record
ConductScience Library. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Papers, record 15959528. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15959528
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid | Major topic |
| Mutation | Major topic |
| Protein-Tyrosine Kinases | Major topic |
| Proto-Oncogene Proteins | Major topic |
| Receptor Protein-Tyrosine Kinases | Major topic |
| Tandem Repeat Sequences | Major topic |
| Acute Disease | |
| Disease-Free Survival | |
| Humans | |
| Prognosis | |
| Proportional Hazards Models | |
| Survival Rate | |
| fms-Like Tyrosine Kinase 3 |
Source PubMed
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 3802833 | Meta-analysis in clinical trials. | Control Clin Trials | 1986 | https://conductscience.org/library/papers/3802833 | PubMed |
| 2 | 10502596 | Acute myeloid leukemia. | N Engl J Med | 1999 | https://conductscience.org/library/papers/10502596 | PubMed |
| 3 | 14726504 | CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. | J Clin Oncol | 2004 | https://conductscience.org/library/papers/14726504 | PubMed |
| 4 | 15167911 | FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. | Hematol J | 2004 | https://conductscience.org/library/papers/15167911 | PubMed |
| 5 | 15059064 | Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. | Eur J Haematol | 2004 | https://conductscience.org/library/papers/15059064 | PubMed |
| 6 | 11535508 | The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. | Blood | 2001 | https://conductscience.org/library/papers/11535508 | PubMed |
| 7 | 11290608 | Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. | Blood | 2001 | https://conductscience.org/library/papers/11290608 | PubMed |
| 8 | 12200684 | Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. | Leukemia | 2002 | https://conductscience.org/library/papers/12200684 | PubMed |
| 9 | 10764154 | Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. | Leukemia | 2000 | https://conductscience.org/library/papers/10764154 | PubMed |
| 10 | 15054042 | Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. | Blood | 2004 | https://conductscience.org/library/papers/15054042 | PubMed |
| 11 | 9746770 | The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. | Blood | 1998 | https://conductscience.org/library/papers/9746770 | PubMed |
| 12 | 15326195 | Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. | J Clin Oncol | 2004 | https://conductscience.org/library/papers/15326195 | PubMed |
| 13 | 12899708 | Flt3 mutations and leukaemia. | Br J Haematol | 2003 | https://conductscience.org/library/papers/12899708 | PubMed |
| 14 | 12522450 | Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). | Hematol J | 2002 | https://conductscience.org/library/papers/12522450 | PubMed |
| 15 | 7786990 | Operating characteristics of a rank correlation test for publication bias. | Biometrics | 1994 | https://conductscience.org/library/papers/7786990 | PubMed |
| 16 | 9751631 | Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. | Cancer Res | 1998 | https://conductscience.org/library/papers/9751631 | PubMed |
| 17 | 12692518 | Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. | Hematol J | 2003 | https://conductscience.org/library/papers/12692518 | PubMed |
| 18 | 10216104 | Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. | Blood | 1999 | https://conductscience.org/library/papers/10216104 | PubMed |
| 19 | 12692519 | Prognostic significance of FLT3 ITD and D835 mutations in AML patients. | Hematol J | 2003 | https://conductscience.org/library/papers/12692519 | PubMed |
| 20 | 11091200 | FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. | Br J Haematol | 2000 | https://conductscience.org/library/papers/11091200 | PubMed |
Cited by118
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 227 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42739525 | Indications for Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation in Adults: State of the Art. | J Clin Med | 2026 | https://conductscience.org/library/papers/42739525 | PubMed |
| 42230462 | Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations. | Blood Res | 2026 | https://conductscience.org/library/papers/42230462 | PubMed |
| 41940985 | Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials. | Ann Hematol | 2026 | https://conductscience.org/library/papers/41940985 | PubMed |
| 41899095 | Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies. | J Clin Med | 2026 | https://conductscience.org/library/papers/41899095 | PubMed |
| 41857060 | Overcoming vascular niche-mediated TKI resistance in acute myeloid leukemia through miR-126 inhibition. | NPJ Syst Biol Appl | 2026 | https://conductscience.org/library/papers/41857060 | PubMed |
| 41537333 | All patients with acute myeloid leukemia and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? - the CON. | Haematologica | 2026 | https://conductscience.org/library/papers/41537333 | PubMed |
| 41082569 | Structure-guided discovery and characterization of novel FLT3 inhibitors for acute myeloid leukemia treatment. | PLoS One | 2025 | https://conductscience.org/library/papers/41082569 | PubMed |
| 40181449 | Assessment of chromatin remodeling of acute myeloid leukemia cells treated with gilteritinib: a case report. | J Med Case Rep | 2025 | https://conductscience.org/library/papers/40181449 | PubMed |
| 39945223 | Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study. | Cancer | 2025 | https://conductscience.org/library/papers/39945223 | PubMed |
| 39884265 | Prognostic Factors, FLT-3 Mutations, and Treatment Outcomes with Pediatric-Inspired Protocols in Adolescent and Young Adults and Adult Patients with Acute Lymphoblastic Leukemia. | Acta Haematol | 2025 | https://conductscience.org/library/papers/39884265 | PubMed |
| 39601608 | New Approvals Advancing Blood Cancer Medicine. | Blood Cancer Discov | 2025 | https://conductscience.org/library/papers/39601608 | PubMed |
| 39237634 | Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. | Leukemia | 2024 | https://conductscience.org/library/papers/39237634 | PubMed |
| 39200232 | Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia. | Biomedicines | 2024 | https://conductscience.org/library/papers/39200232 | PubMed |
| 38915455 | Clinical profile of FTL3-ITD mutation in West Algerian population with acute myeloid leukemia. | Mol Biol Res Commun | 2024 | https://conductscience.org/library/papers/38915455 | PubMed |
| 38663769 | Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITDmut+ Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the United States and Canada. | Transplant Cell Ther | 2024 | https://conductscience.org/library/papers/38663769 | PubMed |
| 38007585 | TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax. | Leukemia | 2024 | https://conductscience.org/library/papers/38007585 | PubMed |
| 37975931 | Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia. | Ann Hematol | 2024 | https://conductscience.org/library/papers/37975931 | PubMed |
| 37847742 | A Year of Advances in Precision Therapy for Blood Cancers. | Blood Cancer Discov | 2023 | https://conductscience.org/library/papers/37847742 | PubMed |
| 37578642 | French Retrospective Database Analysis of Patient Characteristics and Treatment Patterns in Patients with R/R FLT3-Mutated AML: A Registry-Based Cohort Study. | Oncol Ther | 2023 | https://conductscience.org/library/papers/37578642 | PubMed |
| 37457126 | How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication? | Cancer Drug Resist | 2023 | https://conductscience.org/library/papers/37457126 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FLT3 | 2322 | PubTator's text mining | https://conductscience.org/library/genes/2322 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/15959528
GET https://conductscience.org/api/papers/v1/15959528/references?page=2